COVID-19

Although the rapid expansion of telehealth has been an essential part of keeping patients safe during the COVID-19 pandemic, the potential long-term effects of this expansion have not been fully understood.

An expert panel of world-renowned professionals will discuss the latest details on the rapid advances in vaccine development and what they mean to clinicians on the front line.

As clinicians, we must first understand the unique challenges that a patient is facing and then tailor our support to address their specific needs.

As legislators debate the next stimulus package, pharmacists are expressing dismay that the current language does not include designating pharmacists as providers under Medicare Part B for COVID-19 testing and immunization.

Evidence suggests that individuals who have more severe COVID-19 illness requiring hospitalization may still have symptoms that persist even after recovery from infection.

Although the treatment of cancer is facing many challenges, the pandemic is also creating massive amounts of new data with which to educate patients, conduct new research, and make more informed clinical decisions.

This Pharmacy Times Webcast provides an overview of how the COVID-19 pandemic has impacted the treatment and management of patients with cancer.

The researchers found that the effect of ACE inhibitors does not appreciably affect the levels of ACE2 enough to support any changes in the clinical use of these medications.

Drug screening, heart monitoring are critical when using azithromycin and hydroxychloroquine.

Congress is in the middle of discussing this issue, Hogue said, meaning pharmacists need to advocate for provider status immediately.

The latest update from the CDC incorporates evidence that informs the duration of isolation and precautions recommended to prevent transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to others while limiting unnecessary prolonged isolation and unnecessary use of laboratory testing resources.

Patients with cancer diagnosed more than 24 months ago are at an increased risk of severe COVID-19.

Time for Care, a campaign reinforcing the importance of accessing primary health care, has been launched by CVS Health to remind Americans of the importance of prioritizing their health during the coronavirus disease 2019 (COVID-19) pandemic, according to the company.

Top news of the week from Pharmacy Times®.

An increasing amount of evidence points to the possibility of COVID-19 causing cardiovascular-neurological dysfunction.

Long-term care (LTC) pharmacies caring for this population face a myriad of unique obstacles, especially the regulatory framework surrounding them.

Angiotensin peptides are short proteins that regulate the cardiovascular system and are altered in patients with heart failure and those with COVID-19, according to the press release.

Favipiravir is not approved by the FDA. It is being researched in the United States as a potential treatment of COVID-19.

Prepping for flu season in 2020: why the vaccine is more important than ever.

Data show that immunotherapy doesn’t necessarily worsen complications for patients with both COVID-19 and cancer.

As patients return to their routines of returning to pharmacies and the inevitable discussions about COVID-19 begin, it may be a good time to discuss the range of tests that the CDC recommends.

The review also summarized proposed mechanisms behind these wide-ranging systemic effects and provided clinical guidance for physicians, according to a press release.

The test is intended to determine whether someone is currently infected with COVID-19 and if they have been infected in the past.

Without an FDA approved treatment or vaccine for COVID-19, masks are the best form of protection, according to the CDC.

Steven C. Anderson, FASAE, CAE, IOM, president and CEO of the National Association of Chain Drug Stores, has been invited to join the office of Health and Human Services’ new COVID-19 Vaccine Consultation Panel.